Aclarubicin disrupts RNA polymerase II progression at replication-coupled histone genes
- 1Fred Hutchinson Cancer Center
Abstract
Anthracyclines are effective chemotherapeutic agents that cause DNA and chromatin damage. One member of the anthracyclines, aclarubicin, has gained therapeutic interest due to its ability to kill cancer cells through chromatin-based mechanisms, thus avoiding the off-target effects associated with DNA damage. However, the molecular mechanism of action leading to aclarubicin-induced chromatin damage remains elusive. Here we performed Cleavage Under Targets and Tagmentation (CUT&Tag) of RNA polymerase II (Pol II) and other transcriptional regulators in human cells followin aclarubicin treatment. We found that aclarubicin strongly disrupts the replication-coupled histone genes, resulting in a nonproductive accumulation of Pol II transcription machinery here beyond the levels at other genes. We attribute this sensitivity to the dense Pol II loading and rapid transcription of the histone genes, which intensify the chromatin-disrupting effects of aclarubicin. Together, our findings shed light on the mechanism of aclarubicin as an anticancer drug and point to the replication-coupled histone genes as a target for therapeutic intervention.
Related
- NEIL2 regulates RNA polymerase II dynamics to suppress transcription replication conflicts in pancreatic cancer
- Structure of an RNA polymerase ribozyme replication complex
- Polymerase iota coordinates adaptation to replication stress in BRCA2-deficient mammary epithelial cells
- A dedicated motif in human polymerase gamma enables DNA synthesis through replication roadblocks
- Mrc1 and Tof1 Promote Replication Fork Progression and Recovery Independently of Rad53
BibTeX
@misc{nguyen2026aclarubicin,
title = {{Aclarubicin disrupts RNA polymerase II progression at replication-coupled histone genes}},
author = {K. K. Nguyen and M. Wooten and K. Ahmad and S. Henikoff},
howpublished = {bioRxiv},
year = {2026},
month = jul,
doi = {10.64898/2026.07.08.737292},
url = {https://www.biorxiv.org/content/10.64898/2026.07.08.737292v2},
note = {CC BY},
}
RIS
TY - UNPB
TI - Aclarubicin disrupts RNA polymerase II progression at replication-coupled histone genes
AU - K. K. Nguyen
AU - M. Wooten
AU - K. Ahmad
AU - S. Henikoff
PY - 2026
DA - 2026/07/08
PB - bioRxiv
DO - 10.64898/2026.07.08.737292
UR - https://www.biorxiv.org/content/10.64898/2026.07.08.737292v2
AB - Anthracyclines are effective chemotherapeutic agents that cause DNA and chromatin damage. One member of the anthracyclines, aclarubicin, has gained therapeutic interest due to its ability to kill cancer cells through chromatin-based mechanisms, thus avoiding the off-target effects associated with DNA damage. However, the molecular mechanism of action leading to aclarubicin-induced chromatin damage remains elusive. Here we performed Cleavage Under Targets and Tagmentation (CUT&Tag) of RNA polymerase II (Pol II) and other transcriptional regulators in human cells followin aclarubicin treatment. We found that aclarubicin strongly disrupts the replication-coupled histone genes, resulting in a nonproductive accumulation of Pol II transcription machinery here beyond the levels at other genes. We attribute this sensitivity to the dense Pol II loading and rapid transcription of the histone genes, which intensify the chromatin-disrupting effects of aclarubicin. Together, our findings shed light on the mechanism of aclarubicin as an anticancer drug and point to the replication-coupled histone genes as a target for therapeutic intervention.
ER -